Lorenzo Castagnoli

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Melanoma stem cells drive macrophage reprogramming to a hybrid phenotype, modulating melanoma stemness and compromising NK cell-mediated immunity.

Melanoma stem cells drive macrophage reprogramming to a hybrid phenotype, modulating melanoma stemness and compromising NK cell-mediated immunity.

Journal: Frontiers in immunology

Published: September 03, 2025

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 29, 2025

Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer.

Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer.

Journal: Scientific reports

Published: January 17, 2025

Multiple organs exhibit exacerbated cachexia in male mice with colon cancer than females.

Multiple organs exhibit exacerbated cachexia in male mice with colon cancer than females.

Journal: Journal of advanced research

Published: November 11, 2024

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 27, 2024

Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution.

Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution.

Journal: Cancer cell international

Published: December 14, 2023

Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer.

Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: January 03, 2023

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 23, 2022

BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.

BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: February 05, 2022

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.

Journal: Journal of the National Cancer Institute

Published: October 21, 2021

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness.

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness.

Journal: Cancers

Published: July 06, 2021

Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer.

Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer.

Journal: Cancer letters

Published: February 20, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026